Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Other hematologic neoplasm 2Lymphoid 2Tumor-Agnostic 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Leukemia 2Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 413Cytarabine 336fludarabine phosphate 231Rituximab 206Methotrexate 198fludarabine 195venetoclax 174Azacitidine 174Busulfan 169Filgrastim 145Whole-Body Irradiation 143Mycophenolic Acid 143Peripheral Blood Stem Cell Transplantation 141Tacrolimus 138Etoposide 130Vincristine 112Melphalan 110Dexamethasone 109Cyclosporine 102Granulocyte Colony-Stimulating Factor 100Imatinib Mesylate 94Antilymphocyte Serum 91Daunorubicin 90Radiotherapy 84Decitabine 83Dasatinib 76Lenalidomide 75Doxorubicin 70Prednisone 68Idarubicin 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Valacyclovir × Other hematologic neoplasm × Clear all
NCT05536349 2026-04-30

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Other hematologic neoplasm

Leukemia

NCT00562770 2012-07-31

Oral Valganciclovir Versus Valacyclovir

M.D. Anderson Cancer Center

Phase 2 Completed
46 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡